Health and Human Services Secretary Tom Price’s questioning of the benefits of medication-assisted treatment for opioid abuse doesn’t signal a change in federal policy, the Trump administration said Friday.
Price raised concerns Tuesday during a West Virginia listening tour about opioid abuse when he questioned the benefits of addiction medications such as buprenorphine and methadone.
Stay informed.Stay ahead.
Join Washington Examiner for unlimited access to the news, analysis, and commentary that matter most.
See Options
Already a member? Log in
Already a print subscriber? Click here to login/register your account
